INBX

Inhibrx Biosciences, Inc.
CAPPED RATING

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Inhibrx Biosciences, Inc. (INBX) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (F). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
F
Factor Score 0.3 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -10.3
EV / EBITDA -11.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -6.6%
Price Return 12M 14.7%
Catalyst Signal 0.00
Market Cap $1.3B
TTM Revenue $0.0
Price / Sales N/A
ROE N/M

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) C- (1.9) F (0.3) C+ (2.5) C+ (2.6) C- (2.0)
2026-11-05 C+ (2.5) C- (1.9) F (0.3) C+ (2.6) C+ (2.7) C- (2.0)
2026-10-29 C+ (2.5) D+ (1.8) F (0.3) C+ (2.7) C+ (2.7) C- (2.0)
2026-10-22 C+ (2.5) D+ (1.8) F (0.3) B- (2.9) C+ (2.6) C- (2.0)
2026-10-15 C+ (2.5) D+ (1.8) F (0.3) B- (3.1) C+ (2.6) C- (2.1)
Page 1 of 6